Online first
Review paper
Published online: 2024-07-24
Hypomagnesaemia leading to parathyroid dysfunction, hypocalcaemia, and hypokalaemia as a complication of long-term treatment with a proton pump inhibitor — a literature review
Abstract
Proton pump inhibitors (PPIs) are one of the most frequently used medications worldwide. The side effects of this class of drugs have been widely studied. However, their impact on the electrolyte balance is frequently forgotten. Long-term PPI administration can lead to profound electrolyte disturbances, namely hypomagnesaemia as well as, secondary to very low magnesium levels, hypocalcaemia and hypokalaemia.
In this paper we comprehensively review the complexity of the mechanisms contributing to electrolyte imbalance following PPI (proton pump inhibitors) by changing the pH in the intestinal lumen, interfering with the active cellular transport of magnesium regulated by the transient receptor potential melastatin cation channels TRPM6 and TRPM7. The accompanying hypomagnesaemia causes unblocking of the renal outer medullary potassium channel (ROMK), which results in increased potassium loss in the ascending limb of the loop of Henle. Hypokalaemia caused by hypomagnesaemia is resistant to potassium supplementation because the loss of this element in urine increases with the supply of potassium. Additionally, within the calcium-sensitive receptor (CASR), dissociation of magnesium from the alpha subunit of G protein caused by hypomagnesaemia increases its activity, leading to inhibition of PTH secretion and hypocalcaemia resistant to calcium supplementation. All this means that in some patients, chronic use of proton pump inhibitors by affecting the absorption of magnesium, may lead to life-threatening electrolyte disorders.
Keywords: proton pump inhibitorshypomagnesaemiahypocalcaemiahypokalaemiaparathyroid dysfunction
References
- Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J. 2012; 5(Suppl 1): i3–ii14.
- Liamis G, Hoorn EJ, Florentin M, et al. An overview of diagnosis and management of drug-induced hypomagnesemia. Pharmacol Res Perspect. 2021; 9(4): e00829.
- Puchalski AR, Hodge MB. Parathyroid hormone resistance from severe hypomagnesaemia caused by cisplatin. Endokrynol Pol. 2020; 71(6): 577–578.
- Florentin M, Elisaf MS. Proton pump inhibitor-induced hypomagnesemia: A new challenge. World J Nephrol. 2012; 1(6): 151–154.
- Limaye CS, Londhey VA, Nadkart MY, et al. Hypomagnesemia in critically ill medical patients. J Assoc Physicians India. 2011; 59: 19–22.
- Jiang P, Lv Q, Lai T, et al. Does Hypomagnesemia Impact on the Outcome of Patients Admitted to the Intensive Care Unit? A Systematic Review and Meta-Analysis. Shock. 2017; 47(3): 288–295.
- Safavi, M.; Honarmand, A. Admission Hypomagnesemia--Impact on Mortality or Morbidity in Critically Ill Patients. Middle East J Anaesthesiol. 2007; 19: 645–660.
- Soliman HM, Mercan D, Lobo SSM, et al. Development of ionized hypomagnesemia is associated with higher mortality rates. Crit Care Med. 2003; 31(4): 1082–1087.
- Wang D, Zheng J, Hu Q, et al. Magnesium protects against sepsis by blocking gasdermin D N-terminal-induced pyroptosis. Cell Death Differ. 2020; 27(2): 466–481.
- Shin JM, Sachs G, Sachs G, et al. Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology. 2002; 123(5): 1588–1597.
- Heidelbaugh JJ, Kim AH, Chang R, et al. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012; 5(4): 219–232.
- Shaheen NJ, Hansen RA, Morgan DR, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol. 2006; 101(9): 2128–2138.
- Akram F, Huang Y, Lim V, et al. Proton pump inhibitors: Are we still prescribing them without valid indications? Australas Med J. 2014; 7(11): 465–470.
- Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf. 2019; 10: 2042098618809927.
- Whang R, Ryder KW. Frequency of hypomagnesemia and hypermagnesemia. Requested vs routine. JAMA. 1990; 263(22): 3063–3064.
- Park CH, Kim EH, Roh YHo, et al. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS One. 2014; 9(11): e112558.
- Cegla J. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. Ann Clin Biochem. 2015; 52(2): 302.
- Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015; 37(7): 1237–1241.
- Luk CP, Parsons R, Lee YaP, et al. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother. 2013; 47(6): 773–780.
- Srinutta T, Chewcharat A, Takkavatakarn K, et al. Proton pump inhibitors and hypomagnesemia: A meta-analysis of observational studies. Medicine (Baltimore). 2019; 98(44): e17788.
- Research, C. for D.E. and FDA Drug Safety Communication: Low Magnesium Levels Can Be Associated with Long-Term Use of Proton Pump Inhibitor Drugs (PPIs). FDA 2019.
- Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006; 355(17): 1834–1836.
- Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors--a review. Neth J Med. 2009; 67(5): 169–172.
- Druce MR, Thomas JD, Gorrigan RJ. Hypomagnesaemia and Hypocalcaemia with Proton-Pump Inhibitors: An under-Recognised Phenomenon. Endocrine Abstracts. 2009; 19.
- Shabajee N, Lamb EJ, Sturgess I, et al. Omeprazole and Refractory Hypomagnesaemia. Br Med J. 2008; 337(7662): a425.
- Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008; 69(2): 338–341.
- Semb S, Helgstrand F, Hjørne F, et al. Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication. World J Gastroenterol. 2017; 23(37): 6907–6910.
- Vetter T, Lohse MJ. Magnesium and the parathyroid. Curr Opin Nephrol Hypertens. 2002; 11(4): 403–410.
- Quitterer U, Hoffmann M, Freichel M, et al. Paradoxical block of parathormone secretion is mediated by increased activity of G alpha subunits. J Biol Chem. 2001; 276(9): 6763–6769.
- Slepak VZ, Quick MW, Aragay AM, et al. Random mutagenesis of G protein alpha subunit G(o)alpha. Mutations altering nucleotide binding. J Biol Chem. 1993; 268(29): 21889–21894.
- Yamamoto M, Yamaguchi T, Yamauchi M, et al. Acute-onset hypomagnesemia-induced hypocalcemia caused by the refractoriness of bones and renal tubules to parathyroid hormone. J Bone Miner Metab. 2011; 29(6): 752–755.
- Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol. 2007; 18(10): 2649–2652.
- Yang L, Frindt G, Palmer LG. Magnesium modulates ROMK channel-mediated potassium secretion. J Am Soc Nephrol. 2010; 21(12): 2109–2116.
- Schlingmann KP, Weber S, Peters M, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet. 2002; 31(2): 166–170.
- Pietropaolo G, Pugliese D, Armuzzi A, et al. Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy. Nutrients. 2020; 12(11).
- Lu Z, Ding L, Lu Q, et al. Claudins in intestines. Tissue Barriers. 2014; 1(3): e24978.
- Workinger JL, Doyle RP, Bortz J. Challenges in the Diagnosis of Magnesium Status. Nutrients. 2018; 10(9).
- Schlingmann KP, Waldegger S, Konrad M, et al. TRPM6 and TRPM7--Gatekeepers of human magnesium metabolism. Biochim Biophys Acta. 2007; 1772(8): 813–821.
- Ellison DH, Maeoka Y, McCormick JA. Molecular Mechanisms of Renal Magnesium Reabsorption. J Am Soc Nephrol. 2021; 32(9): 2125–2136.
- Hou J, Renigunta A, Gomes AS, et al. Claudin-16 and claudin-19 interaction is required for their assembly into tight junctions and for renal reabsorption of magnesium. Proc Natl Acad Sci U S A. 2009; 106(36): 15350–15355.
- Thebault S, Alexander RT, Tiel Groenestege WM, et al. EGF increases TRPM6 activity and surface expression. J Am Soc Nephrol. 2009; 20(1): 78–85.
- Groenestege WM, Thébault S, van der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest. 2007; 117(8): 2260–2267.
- Petrelli F, Borgonovo K, Cabiddu M, et al. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf. 2012; 11 Suppl 1: S9–19.
- Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM. 2010; 103(6): 387–395.
- Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol. 2011; 27(2): 180–185.
- Michalek W, Semler JR, Kuo B. Impact of acid suppression on upper gastrointestinal pH and motility. Dig Dis Sci. 2011; 56(6): 1735–1742.
- Novak I, Wang J, Henriksen KL, et al. Pancreatic bicarbonate secretion involves two proton pumps. J Biol Chem. 2011; 286(1): 280–289.
- Topala CN, Groenestege WT, Thébault S, et al. Molecular determinants of permeation through the cation channel TRPM6. Cell Calcium. 2007; 41(6): 513–523.
- Li M, Du J, Jiang J, et al. Molecular determinants of Mg2+ and Ca2+ permeability and pH sensitivity in TRPM6 and TRPM7. J Biol Chem. 2007; 282(35): 25817–25830.
- Lameris ALL, Hess MW, van Kruijsbergen I, et al. Omeprazole enhances the colonic expression of the Mg(2+) transporter TRPM6. Pflugers Arch. 2013; 465(11): 1613–1620.
- Chubanov V, Waldegger S, Mederos y Schnitzler M, et al. Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. Proc Natl Acad Sci U S A. 2004; 101(9): 2894–2899.
- Misiorowski W, Dedecjus M, Konstantynowicz J, et al. Management of hypoparathyroidism: a Position Statement of the Expert Group of the Polish Society of Endocrinology. Endokrynol Pol. 2023; 74(5): 447–467.
